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Abstract
Objective—This study investigates whether 99mTc pyrophosphate (PYP) imaging provides a
quantitative non-invasive assessment of the extent of electroporation injury, and of the effect of
poloxamer in vivo on electroporated skeletal muscle.
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Methods—High-voltage electrical shock was used to produce electroporation injury in an
anesthetized rat’s hind limb. In each experiment, the injured limb was treated intravenously by
either poloxamer-188, dextran, or saline, and subsequently imaged with 99mTc PYP. The
radiotracer’s temporal behavior among the experimental groups was compared using curve fitting
of time–activity curves from the dynamic image data.
Results—The washout kinetics of 99mTc PYP changed in proportion to the electric current
magnitude that produced electroporation. Also, 99mTc PYP washout from electroporated muscle
differed between poloxamer-188 treatment and saline treatment. Finally, 10-kDa dextran treatment
of electroporated muscle altered 99mTc PYP washout less than poloxamer-188 treatment.
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Conclusions—Behavior of 99mTc PYP in electroporated muscle appears to be an indicator of
the amount of electroporation injury. Compared to saline, intravenous polaxamer-188 treatment
reduced the amount of 99mTc PYP uptake. Coupled to results showing poloxamer-188 seals
ruptured cellular membranes, lessens the extent of electroporation injury and improves cell
viability, 99mTc PYP imaging appears to be a useful in vivo monitoring tool for the extent of
electroporation injury.

★This work was conducted in accordance with institutional animal care and use policies and radiation protection practices.
*

Corresponding author: Tel.: +1 225 578 2740; fax: +1 225 578 0824. **Corresponding author. Tel.: +1 773 702 6302; fax: +1 773 702
1634.
1The founder of Maroon Biotech; owned in part by The University of Chicago, Maroon Biotech is the licensee of patents derived from
Dr. Lee’s research on poloxamer applications to burn injury.
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1. Introduction
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Since the development of electrical devices and electrical power distribution systems,
electrical injury has been a serious problem [1]. Massive trauma can result from highvoltage shock by power–frequency electrical currents [2]. In biological tissues, the severity
of response to electrical injury is related to the current involved. Responses range from
muscle twitch and mild pain at small current to cardiac defibrillation at high currents [3].
Nerves and muscles are particularly susceptible to damage from electric shock, in part
because of the extreme voltage gradients that can occur along these long cells. Burns and
cellular disruption result directly from heat generated by an electric arc and the passage of
electric current over and through the body, as well as from hot or burning debris [1].
Neuropsychological disorders can result both from physical trauma and emotional reaction
to the injury [4,5]. A variety of approaches are used for the treatment of electrical injury,
including fluid resuscitation, metabolic and respiratory support, surgical debridement, and
skin grafting [6–8]. New therapeutic methods, such as immunologic therapy and artificial
skin materials, may provide significant benefit. Basic research into the mechanisms of
electrical injury is providing new insight into cellular-level approaches for limiting and
repairing damage.
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Historically, the damage from high-voltage injury was thought to be a direct result of heat
production as current passes through tissue. Heating causes macromolecules to deform and
become unable to perform their cellular functions; this can disrupt cellular metabolism and
compromise structural integrity, resulting in cell death. Nerve cells typically have low
resistivity, decreasing the likelihood of heating, but nerve cells are particularly susceptible to
electrical injury. It is not uncommon for electrical shock victims to present with deep muscle
and nerve damage, simultaneous with minimal signs of thermal injury at the site of contact
[9,10]. This suggests the presence of damage mechanisms in addition to thermal damage
[11].
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Electroporation has been shown to be another cause of damage in high-voltage electrical
injury [12,13]. One postulated mechanism is that field gradients during electric shock force
polar water molecules into molecular-scale defects in the cellular membrane; the result is
enlargement of the defects to form pores [14]. In electroporated tissues, cellular membranes
are perforated, interfering with normal metabolic function. If the membrane damage can be
patched, the cell may be able to resume functioning and survive the injury. Poloxamer, a
type of surfactant, appears to form a suitable patch [15].
Poloxamers are non-toxic nonionic surface-active triblock copolymers [16]. Poloxamer’s
structure, with a hydrophobic region bracketed by hydrophilic regions, has similarities to the
phospholipid bilayer that comprises cellular membranes. Research indicates poloxamers
associate themselves with a damaged membrane, coating exposed hydrophobic regions of
the membrane and plugging water-enlarged pores [15,17]. Shielded from degradatory
Burns. Author manuscript; available in PMC 2018 September 16.
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influences, the cell would be provided the opportunity to recover, repair the membrane
damage, and resume normal function.
The potential therapeutic effects of poloxamer-188 have been reported by a variety of
researchers for a variety of types of tissue injury. Poloxamer-188 has been shown to limit the
damage from electroporation to membranes [15,18] and to improve tissue viability [15,19].
Poloxamer-188 increases capillary circulation in several types of injuries [19,20].
Poloxamer-188 has also been reported to limit damage and improve recovery from
mechanical, chemical, thermal, and radiation damage as well as ischemia-reperfusion injury
in a variety of tissue types that include neurons, muscles, and heart [21–27]. The bulk of
studies have investigated the effects of poloxamer-188 in vitro or in animal models. The
literature includes some human case studies, as well as evident interest in using poloxamers
in conjunction with electroporation as a tool for transmembrane drug delivery.
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1.1. Radiotracer imaging of electrical injury
A number of trauma types can damage skeletal muscle and other soft tissues. Besides
electrical injury, frostbite, ischemia and infections result in soft tissue injury. A variety of
diagnostic methods are used commonly to evaluate soft tissue injury. These include visual
assessment, histological and blood chemistry analysis, and radiological imaging.
Magnetic resonance imaging (MRI) is a valuable diagnostic tool because it provides
exceptional delineation of soft tissues compared to other types of radiological imaging. The
utility of MRI for electrical injury has been reported in several instances [28–32]. The detail
visible from MRI can help to guide the surgeon in removal of tissue; MRI also visualizes the
extent of deep tissue damage without the need for invasive exploration.
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Functional imaging is also useful for assessing soft tissue injury. Compared to the
anatomical visualization provided by MRI and CT scans, functional images show the
physiological behavior of an organ system. With appropriate techniques, factors such as
tissue perfusion, inflammation, metabolism and necrosis can be visualized. While techniques
such as functional MRI have not yet been reported for assessing soft tissue damage,
radiotracer imaging has been used extensively for assessment of soft tissue injury [33–36]. A
number of tracers, particularly 99mTc-labeled phosphonates and 99mTc pyrophosphate
(PYP), accumulate in damaged soft tissue [37–39]. The degree of tracer accumulation is
often a good index of the extent of tissue damage [40–42].
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Over the past two decades, radiotracer imaging has been used to assess the extent of damage
in electrical injury victims [43–48]. Radiotracer imaging can delineate necrotic regions from
viable tissue by visualizing the altered metabolism or function in these regions. In many
cases, areas of abnormal tracer uptake may not appear visually necrotic until hours or days
after the injury. The results of radiotracer imaging can assist in planning the surgical and
therapeutic management of an injury [49]. A variety of radiopharmaceuticals are or could
prove useful for clinical imaging of electrical injury of soft tissues, including 99mTc PYP,
99mTc hexakis-2-methoxyisobutylisonitrile (MIBI), 133Xe, and 18F-fluorodeoxyglucose
(FDG).
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Our study reports on 99mTc PYP imaging of electroporation injury in an in vivo rat model.
Alterations in 99mTc PYP kinetics caused by differing amounts of electroporation injury and
different therapeutic agents were assessed by region of interest (ROI) analysis of dynamic
radiotracer images and curve fitting. The purpose of our study was to determine if 99mTc
PYP imaging provides a quantitative non-invasive assessment of the extent of
electroporation injury and of the effect of poloxamer treatment on electroporated skeletal
muscle.

2. Materials and methods
Fig. 1 shows the experimental equipment used in this work. The components are described
in the following sections.
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2.1. In vivo model of electroporation
This research utilized the in vivo model of electroporation developed by Block et al. [50].
This model provides a means to study electroporation in the absence of thermal damage, in
the skeletal muscle of the hind limb of an anesthetized rat; our study focuses on visualizing
damage to the biceps femoris muscle. Briefly, the centerpiece of the model is a female
Sprague–Dawley rat kept fully anesthetized by continuous intraperitoneal infusion of a
mixture of ketamine and xylazine. The animals used in this work weighed 280–350 g and all
were non-pregnant and free of disease. A jugular cannula introduced radiotracer, saline, and
therapeutic agents directly into the bloodstream of the animal. All experiments were not
survived; euthanasia at the end of the experiment was accomplished with an overdose of
xylazine administered either through the jugular cannula or directly into the heart.
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As in Block’s model, electroporation damage was produced throughout the muscle of one
hind limb by applying a sequence of high-voltage current-regulated dc electrical pulses from
the ankle to the base of the tail [50]. Electric field strength of approximately 150 V/cm was
delivered at a constant current between the ankle and base of the tail. The maximum
available current was 1.85 A. The pulse duration was 4 ms, equivalent to the length of time
that a 60 Hz sine wave exceeds its root-mean-square (rms) amplitude in each half-cycle.
Twelve pulses were applied from the base of the tail to the ankle over a 2-min span; the 10-s
interval between pulses minimizes heat accumulation in the limb.
2.2. High-resolution small-field-of-view gamma camera
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The imaging system used in this work was a high-resolution small-field-of-view gamma
camera [51]. The camera provides a 64 × 64 pixel, 4.8 cm × 4.8 cm field of view, sufficient
to image one hind limb of the rats used in this study; a second camera was used to image the
contralateral (unshocked) limb in some experiments. With its high-resolution collimator, the
imaging resolution is 5.4 mm full-width-at-half-maximum at a 5 cm depth.
The camera software provides automated acquisition of dynamic image data; each image is
2 min in duration, with a 2.4 min interval between the start of successive images. (The 0.4min lag was the length of time required by the operator to manually save each image to disk
in a pre-automated version of the software; the lag was maintained to facilitate comparison
with earlier imaging studies.) Region of interest (ROI) analysis and curve-fitting of the
Burns. Author manuscript; available in PMC 2018 September 16.
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dynamic image data was performed off-line using analysis programs written in the
Interactive Data Language (IDL) software (Research Systems, Boulder, CO).
2.3. Selection of radiotracer
Four radiotracers were considered for use in this research. These were 99mTc PYP, 99mTc
diethylenetriaminepentaacetate (DTPA), 99mTc hexakis-2-methoxyisobutylisonitrile (MIBI),
and 201Tl thallous chloride. Each tracer has biological characteristics that make it potentially
useful for imaging electroporation injury [52]. Technetium-99m PYP was selected as the
best candidate radiotracer for imaging electroporation in the in vivo rat model.
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Technetium-99m PYP is well known as a tracer for soft tissue injury [37–40]. It accumulates
in damaged soft tissue, clears moderately quickly from undamaged soft tissue, and
accumulates over time in bone. The biggest drawback to using 99mTc PYP is that the
mechanism of its accumulation in damaged tissue is not well understood; it is believed to
follow calcium in cellular function [53–55]. The exact structure of 99mTc PYP is not known;
PYP forms a complex with technetium in the presence of a tin catalyst, but the number of
PYP molecules per technetium atom has never been determined conclusively. Estimates
range from one to five PYP molecules per technetium atom; it appears possible that the
number is variable.
2.4. Therapeutic agents
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The two therapeutic agents investigated in this work were poloxamer and dextran; saline was
used as a control. Poloxamer-188 (Pluronic F68, BASF Corp., Florham Park, NJ) was
examined at 17 and 68 mg dosages. The dextran experiments used 10 or 40 kDa neutral
dextran (Sigma Chemicals, St. Louis, MO) at a 17 mg dosage. Ten kilodaltons dextran is
similar in molecular weight to poloxamer-188; 40 kDa dextran is used clinically as a plasma
expander in electrical injury victims. Saline was used in control experiments. Saline-treated
unshocked muscle provided a normal baseline for comparison. In all cases, a solution
volume of 0.4 ml (e.g., 68 mg of poloxamer-188 was dissolved in saline to produce a volume
of 0.4 ml) was injected through the jugular cannula. Table 1 summarizes the parameters of
the experimental protocol, including the numbers of animals in each experimental group.
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The blood volume of a 300 g rat is approximately 17 ml. Thus, the approximate effective
blood concentrations in the groups of experimental animals treated with 17 and 68 mg of
poloxamer-188 are 1 and 4 mg/ml, respectively. A blood concentration of 1 mg/ml
approximates the dosage that might be administered to patients in clinical trials of
poloxamer therapy for electroporation. A 4 mg/ml concentration is close to critical micelle
concentration for poloxamer-188; above this concentration, poloxamer is expected to form
micelles, thereby potentially limiting interactions with ruptured cell membranes.
2.5. Imaging protocol
The experimental protocol for investigating poloxamer calls for the investigative agent to be
injected through the jugular cannula at ten minutes after shock. In control experiments,
saline was injected at this time. Technetium-99m PYP was injected through the cannula at
30 min post-shock. An activity of 37 × 7.4 MBq (1.0 × 0.2 mCi) in 0.4 ml saline was
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injected. The small gamma camera acquired serial, posterior view images of the shocked
hind limb. Each image was 2 min in duration with a new image starting every 2.4 min. The
imaging phase of each experiment extended for 3.5 h post-shock; 88–90 images were
usually obtained. During data analysis, the dynamic image data were reviewed. If a cine
image loop showed that the limb moved or that radioactive urine leaked into the field of
view, the data for that experiment were rejected from further analysis.
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Experiments that had excessive vascular damage in the hind limb were excluded also. While
the focus of this research is electroporation of skeletal muscle, the electroporation protocol
cannot avoid doing some damage to the vasculature of the shocked limb. In some
experiments, the amount of tracer uptake in a shocked limb would never rise above the level
seen in unshocked limbs. This lack of tracer delivery was due most likely to compromised
vasculature. To assess the extent of vascular damage in each experiment, lissamine green
was injected through the jugular catheter 10 min before euthanasia. Lissamine green is a dye
whose distribution depends on tissue perfusion; poor staining of the muscle indicates
compromised vasculature. After euthanasia, the biceps femoralis muscle of the shocked and
contralateral limbs would be exposed and visually inspected. If the shocked muscle showed
little staining compared to the unshocked limb, the vasculature was deemed compromised
and the data rejected. We noted the correlation that experiments where the muscle of the
shocked limb showed little staining with lissamine green, the tracer uptake consistently was
below unshocked saline-treated levels at all times. Note that the lissamine green observation
was always recorded before any image data analysis; rejection of a data set was based on the
lissamine green staining, not on the radiotracer image data.
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The research plan was to acquire ten experiments at 1.85 A of applied current for each type
and concentration of therapeutic agent and five experiments each for the unshocked data sets
and the data sets that compared the other levels of applied current. Experiments where
compromised vasculature was noted via lissamine green staining, were not counted towards
each category’s total and an additional experiment was done in these cases. Instances of
limb movement or radioactive urine in the field of view were identified later during the data
analysis, and additional experiments were not done to replace these. The final numbers of
experiments in each data set are noted in the legends of the figures and in Table 1. Four
additional experiments were collected for the 17 mg 40 kDa dextran data set while training a
new lab employee; these experiments were included in the analysis because there were no
specific procedural issues to justify excluding them from the analysis. Approximately 80
experiments in total were performed to obtain the data reported here.
2.6. ROI analysis
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ROI analysis was used to extract time–activity curves (TACs) from the dynamic image data.
Using display and analysis code written in IDL, an 8 × 7-pixel (6 mm × 5.25 mm) ROI
positioned over the biceps femoralis muscle was used to compute a TAC for each
experiment. The TACs were positioned using a composite image produced by summing all
images from the dynamic data set. The location of the knee and the outline of soft tissue of
the hind limb were clearly visible in the composite image; the ROI was placed visually over
the soft tissue below the bones of the lower limb, as shown in Fig. 2. The TACs from
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individual experiments were averaged to yield a mean curve for each data set. To provide a
quantitative characterization of the ROI data for 99mTc PYP, the average TACs were fit by a
least-squares algorithm to a simple mathematical model. The fitting function uses an
exponential decay on a constant background level, with the form:
f (t) = A exp ( − Bt) + C

(1)

to describe the washout of tracer. Tracer uptake was not modeled; uptake occurs rapidly
during the first two minutes after radiotracer injection and was not recorded by our imaging
protocol.
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The fitted parameters for the curves were compared statistically to determine the level of
significance of differences in the fitted parameters. Student’s t-value was computed for pairs
of corresponding average fitted parameters between the different data sets. A level of p <
0.01 was chosen to indicate the level of significance. This relatively stringent level was
chosen because multiple comparisons between data sets are made. Each data set is compared
to six other data sets; consequently, the selected p-value corresponds to significance
approximately at a 95% confidence level.

3. Results
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Technetium-99m PYP is known to accumulate in damaged soft tissue, and the experimental
validation of the in vivo electroporation model [50] confirmed that 99mTc PYP accumulates
in electroporated tissue. Fig. 3 shows that the TAC magnitudes for 99mTc PYP are
proportional to the current magnitude used to produce electroporation and, thus, indicative
of the amount of electroporation injury. This result indicates that 99mTc PYP can serve as an
index to the extent of electroporation injury. Higher uptake means more damage and lower
uptake means less damage. This provides a means for in vivo assessment of the effect of
poloxamer-188 on electroporated muscle. If membrane damage is being reduced by
poloxamer, the uptake of PYP should be less than in muscle to which poloxamer was not
administered.
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To rule out the possibility that any observed change in 99mTc PYP kinetics in poloxamertreated muscle is caused by direct molecular interaction of poloxamer with PYP,
independent of the presence of tissue damage, a set of poloxamer-treated unshocked
experiments were conducted. Fig. 4 shows the average TAC for unshocked muscle treated
with 17 mg poloxamer-188. The TAC magnitude is marginally higher at all times than that
for unshocked muscle treated with saline. This slight increase most likely results from
poloxamer-188 acting as a plasma expander [56]. Therefore, any perceived change in tracer
behavior includes a small fractional increase due to this effect. In addition, this effect is
opposite in magnitude to the observed changes in PYP uptake in poloxamer-treated shocked
muscle (see below), giving confidence that the observed decreases in the poloxamer-treated
shocked experiments are due primarily to the effects of poloxamer on the damaged tissue,
rather than from direct interaction between the 99mTc PYP and the poloxamer. One could
remove the effect of this plasma-expansion increase from the other data sets by subtracting
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away the average unshocked-poloxamer-treated TAC. However, the increase in TAC
magnitude is small (relative to the large increase seen in shocked muscle) so we chose not to
implement a correction to the other image data for this effect.
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Shown in Fig. 5 are average TACs for 99mTc PYP in unshocked saline-treated, shocked
saline-treated and shocked poloxamer-treated muscle. It is immediately apparent that the
magnitude of PYP uptake in electroporated muscle is substantially higher than in normal
muscle. Additionally, while the temporal behavior is similar for saline-treated electroporated
and saline-treated normal muscle, the behavior appears different for electroporated muscle
that has been treated with 17 mg of poloxamer-188. The relatively constant value of the TAC
for poloxamer treatment contrasts sharply with the exponential shape of the saline-treated
curves. One also sees that treatment with 68 mg of poloxamer-188 results in a TAC that is
similar to that for saline-treated muscle. A pertinent question here is what causes this
different behavior of PYP in 17 mg poloxamer-188 treated muscle. Ideally, the altered
kinetics are due to sealing of ruptured membranes by poloxamer-188, leading to improved
long-term cell viability.
Fig. 6 illustrates the results of treating electroporated muscle with 17 mg of 10 or 40 kDa
neutral dextran. Forty kilodaltons dextran causes an initial marginal decrease in tracer uptake
compared to saline, but little difference is apparent at 4 h post-shock. A larger initial
decrease is seen with 10 kDa dextran but the difference is negligible 4 h post-shock.
Compared to shocked saline-treated muscle, tracer washout appears slightly faster for 40
kDa dextran and substantially faster for 10 kDa dextran. Fig. 7 shows that treatment with 17
mg of 10 kDa dextran does not alter the kinetics of 99mTc PYP as much as treatment with 17
mg of poloxamer-188 does.
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Table 2 lists the fitted values from the average curves; significance levels for pairs of average
parameters from individual fitted curves are given in Table 3. Entries with p < 0.01
(corresponding approximately to a 95% confidence level for multiple comparisons between
the different experimental groups) are presented in bold typeface. One of the most notable
results is that the 17 mg poloxamer-treated data do not show any particular difference in its
B-parameter from the other data sets; this indicates that the washout rate is unchanged, so
the altered appearance of the curve is due to a change in initial magnitude (A-parameter).
Another observation is that the unshocked saline-treated data are not significantly different
in any of the fitting parameters from the unshocked poloxamer-treated data. Finally, one
notes that the 1.85 A shocked saline-treated and 1.85 A shocked poloxamer-treated data are
marginally different at best in the C, or baseline, parameter.

Author Manuscript

4. Discussion
Our study demonstrates that the in vivo electroporation model is a useful tool for the study
of the basic pathophysiologic process of electroporation. Radiotracer imaging of the in vivo
model provides a means for quantifying the extent of electroporation injury and the effects
of poloxamer-188 and other potential therapeutic agents on electroporated muscle.
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Because of its history as a tracer for soft-tissue injury, 99mTc PYP was expected to be a good
choice for use in the electroporation research. The curves in Fig. 5 show that the PYP TAC is
substantially different in electroporated muscle treated with 17 mg poloxamer-188 than in
saline-treated electroporated muscle. In particular, PYP reaches a steady-state level for the
poloxamer case that is noticeably less than the plateau level for saline treatment. However,
one notes that at the ~95% confidence level chosen for comparison, the A and C parameters
for these data sets are not significantly different. Based on the apparent substantial difference
in the TACs, one expects that with the addition of more experiments to these data sets, the
errors bars will decrease in magnitude and the level of statistical significance will improve.
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In unshocked muscle, PYP kinetics are not significantly different if the muscle is treated
with 17 mg poloxamer-188 than if it is treated with saline. The baseline parameters for the
unshocked data sets are significantly different from all the shocked data sets, as one expects
visually from the TACs in Figs. 4–7.
For all data sets, the rate parameters for the TACs are not significantly different between any
of the data sets. For the exponential-plus-constant-background fitting function, the Bparameter of the fitted TACs is not significantly different between either unshocked salinetreated and shocked saline-treated experiments or shocked saline-treated and shocked
poloxamer-treated experiments. This indicates that the washout mechanism of PYP is
unaltered by shocking or by treatment with poloxamer-188, while the mechanisms driving
uptake and the equilibrium distribution are affected.
4.1. Radiotracers for future investigation
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Technetium-99m PYP was chosen for this work primarily because of its extensive history as
a tracer for soft tissue injury. However, 99mTc PYP was not the only possible choice. In
addition to other tracers discussed in Ref. [52], 133Xe and 18F-FDG could be useful for
clinical and research imaging of electroporation, but these were not considered practical for
the current research. FDG has been reported for clinically assessing skeletal muscle viability
[57]. Although, the shielding and collimation of the small gamma camera used in this study
were not designed for 511 keV imaging, FDG imaging of the in vivo model of
electroporation seems an interesting prospect, given the current availability of small animal
PET scanners (e.g., microPET, CTI Molecular Imaging, Knoxville, TN). Xenon-133 was
rejected as impractical for this investigation because of its long half-life and difficulties in
achieving a specific activity of aqueous 133Xe that was high enough to calibrate the small
gamma camera system.
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Technetium-99m-labeled dextran and 99mTc-labeled poloxamer potentially would be ideal
tracers for research and clinical investigations. Technetium-99m poloxamer would be
especially attractive for investigating the interaction of poloxamer with electroporated
membranes. While dextran has been successfully radiolabeled with 99mTc [58], the
feasibility of developing 99mTc-labeled poloxamer for in vivo imaging is an open question;
18F-labeled poloxamer for PET imaging may be more reasonable.
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5. Conclusion
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In summary, the in vivo electroporation model [50] showed that electroporation without
significant Joule heating can occur during high-voltage electrical shock. The model is
clinically realistic and provides a means for studying the basic pathophysiology of
electroporation injury. Our study used the in vivo model to study the effect of poloxamer on
electroporated muscle. Intravenous injection of poloxamer-188 significantly lessens the
amount of 99mTc PYP retained by electroporated skeletal muscle. Taken in conjunction with
in vitro research reported in the literature [17,18,59], as well as in vivo studies that indicated
poloxamer-188 minimizes damage and improves viability [15,19,23,25], the results from our
work indicate that poloxamer may have a beneficial therapeutic effect on electroporated
cells. Radiotracer imaging of electroporated skeletal muscle appears to be a viable noninvasive method for judging the extent of injury and tissue viability. Further work on
modeling the kinetics of 99mTc PYP in poloxamer-treated electroporated tissues may
provide the ability to quantify extent of injury from dynamic image data.
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Photograph of the experimental setup, showing the anesthetized animal and the small
gamma camera. The anesthetic infusion pump is seen at left and a syringe coupled to the
jugular catheter is in the foreground; a pumped-water heating pad maintains the animal’s
body temperature.
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Fig. 2.

Typical posterior-view image of 99mTc PYP in the hind limbs. The left limb was shocked
with 1.85 A pulses and 99mTc PYP was injected at 30 min post-shock. The left limb was
imaged for 12 min at 105 min post-shock; the right limb was imaged for 12 min at 120 min
post-shock. The muscle of the shocked limb (left) shows substantially more uptake than does
the muscle of the unshocked limb (right). The white boxes illustrate the typical placement of
ROIs over the muscle.
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Fig. 3.

TACs for 99mTc PYP in saline-treated electroporated muscle vs. applied current. Saline was
injected 10 min post-shock (dotted line) and radiotracer was injected 30 min post-shock
(dashed line). Error bars represent S.E.M.
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Fig. 4.

TAC of 99mTc PYP in unshocked muscle treated with 17 mg poloxamer-188. The TACs for
unshocked saline-treated and 1.85 A-shocked saline-treated muscle are shown for
comparison. Saline or polox-amer-188 was injected 10 min post-shock (dotted line) and
radiotracer was injected 30 min post-shock (dashed line). Error bars represent S.E.M.
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Fig. 5.

TACs of 99mTc PYP in poloxamer-188-treated electroporated muscle. TACs for unshocked
saline-treated muscle and saline-treated muscle shocked at 1.85 A are shown for
comparison. Therapeutic agent was injected 10 min post-shock (dotted line); radiotracer was
injected 30 min post-shock (dashed line). Error bars represent S.E.M.
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Fig. 6.

TACs of 99mTc PYP for 1.85 A-shocked electroporated muscle treated with 10 and 40 kDa
dextran. TACs for unshocked saline-treated muscle and saline-treated muscle shocked at
1.85 A are shown for comparison. Therapeutic agent was injected 10 min post-shock (dotted
line); radiotracer was injected 30 min post-shock (dashed line). Error bars represent S.E.M.
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Fig. 7.

Comparison of TACs for treatment with 17 mg poloxamer-188 and 17 mg 10 kDa dextran.
The TACs for 1.85 A-shocked and unshocked muscle treated with saline are shown for
comparison. Therapeutic agent was injected 10 min post-shock (dotted line); radiotracer was
injected 30 min post-shock (dashed line). Error bars represent S.E.M.
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Summary of experimental parameters
Common parameters
Pulse sequence
12 constant-current pulses
4 ms duration each
Field strength of ~150 V/cm in hind limb
10 s interval between pulses
Injection times
Therapeutic agent: 10 min post-shock
Radiotracer: 30 min post-shock
Radiotracer
99mTc

pyrophosphate

Author Manuscript

Nominal injected activity: 37 ± 7.4 MBq (1.0 ± 0.2 mCi)
Image acquisition
2 min duration for each image
New image starting every 2.4 min
~3.5 h (88–90 images)
Experimental group namea

No. of rats

Shocked? (current)

Therapeutic agent
Type

0 A saline

4

No

Saline

0 A 17 mg poloxamer-188

3

No

Poloxamer-188

0.5 A saline

2

Yes (0.5 A)

Saline

–

1.0 A saline

4

Yes (1.0 A)

Saline

–

Author Manuscript

1.85 A saline

–
17 mg (1 mg/ml)

8

Yes (1.85 A)

Saline

10

Yes (1.85 A)

Poloxamer-188

17 mg (1 mg/ml)

1.85 A 68 mg poloxamer-188

4

Yes (1.85 A)

Poloxamer-188

68 mg (4 mg/ml)

1.85 A 17 mg 10 kDa dextran

10

Yes (1.85 A)

10 kDa dextran

17 mg (1 mg/ml)

1.85 A 17 mg 40 kDa dextran

14

Yes (1.85 A)

40 kDa dextran

17 mg (1 mg/ml)

1.85 A 17 mg poloxamer-188

a

Amountb (blood concc)

–

Designated by applied current and therapeutic agent.

b

Dissolved in 0.4 ml of saline.

c

Assuming an average blood volume of 17 ml.

Author Manuscript
Burns. Author manuscript; available in PMC 2018 September 16.

Matthews et al.

Page 22

Table 2

Author Manuscript

ROI-derived fitted time-activity curve parameters
Experimental groupa

Fitting parameterb
Ac

a

Bd

Cc

0 A saline

538.5

0.0359

53.0

1.85 A saline

251.1

0.0146

239.3

1.85 A 17 mg poloxamer-188

24.0

0.0021

162.5

1.85 A 68 mg poloxamer-188

195.2

0.0193

274.1

1.85 A 17 mg 10-kDa dextran

966.2

0.0781

244.9

1.85 A 17 mg 40 kDa dextran

174.6

0.0151

250.2

0 A 17 mg poloxamer-188

696.7

0.0409

87.0

Author Manuscript

Designated by applied current and therapeutic agent.

b

Exponential decay + constant background model: f(t) = A exp(−Bt) + C.

c

Magnitude; in units of counts in ROI per 2-min image.

d

Decay constant; in units of min−1.
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Statistical significance of fitted TAC parameters
For experimental group

1.85 A saline

0 A saline

Author Manuscript

1.85 A 17 mg poloxamer-188

1.85 A 68 mg poloxamer-188

1.85 A 17 mg 10 kDa dextran

Author Manuscript

1.85 A 17 mg 40 kDa dextran

a

Compared to

p-Valuea,b
A

B

C

1.85 A 17 mg poloxamer-188

0.035

0.856

0.023

1.85 A 68 mg poloxamer-188

0.271

0.569

0.912

1.85 A 17 mg 10 kDa dextran

0.217

0.360

0.845

1.85 A 17 mg 40 kDa dextran

0.775

0.335

0.905

0 A 17 mg poloxamer-188

0.125

0.244

0.003

0 A saline

0.132

0.177

0.0003

1.85 A 17 mg poloxamer-188

0.0003

0.544

0.0004

1.85 A 68 mg poloxamer-188

0.006

0.036

0.0001

1.85 A 17 mg 10 kDa dextran

0.419

0.774

0.006

1.85 A 17 mg 40 kDa dextran

0.038

0.016

0.0002

0 A 17 mg poloxamer-188

0.798

0.979

0.020

1.85 A 68 mg poloxamer-188

0.027

0.642

0.007

1.85 A 17 mg 10 kDa dextran

0.241

0.521

0.136

1.85 A 17 mg 40 kDa dextran

0.019

0.394

0.029

0 A 17 mg poloxamer-188

0.0001

0.610

0.007

1.85 A 17 mg 10 kDa dextran

0.325

0.388

0.810

1.85 A 17 mg 40 kDa dextran

0.274

0.847

0.833

0 A 17 mg poloxamer-188

0.002

0.065

0.0009

1.85 A 17 mg 40 kDa dextran

0.111

0.129

0.902

0-A 17-mg poloxamer-188

0.496

0.803

0.033

0 A 17 mg poloxamer-188

0.036

0.033

0.003

p-Value for Student’s t-statistic computed between the corresponding pair of fitted parameter values for the two datasets indicated.

b

Bold values indicate the corresponding pair of fitted parameters is significantly different at the p < 0.01 level.
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